Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cytokinetics (CYTK) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on UnitedHealth (UNH – Research Report), Cytokinetics (CYTK – Research Report) and Moderna (MRNA – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
UnitedHealth (UNH)
Barclays analyst Andrew Mok CFA maintained a Buy rating on UnitedHealth today and set a price target of $391.00. The company’s shares closed last Tuesday at $282.70.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $396.71 average price target, representing a 34.9% upside. In a report released yesterday, TipRanks – OpenAI also upgraded the stock to Buy with a $399.00 price target.
See the top stocks recommended by analysts >>
Cytokinetics (CYTK)
In a report released today, Gena Wang from Barclays maintained a Buy rating on Cytokinetics, with a price target of $87.00. The company’s shares closed last Tuesday at $64.01.
According to TipRanks.com, Wang is a 3-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $91.07, representing a 43.9% upside. In a report issued on January 13, Piper Sandler also maintained a Buy rating on the stock with a $107.00 price target.
Moderna (MRNA)
DBS analyst Nico Chen maintained a Hold rating on Moderna today and set a price target of $45.00. The company’s shares closed last Tuesday at $45.45, close to its 52-week low of $29.25.
According to TipRanks.com, Chen is a 4-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $31.67, implying a -34.1% downside from current levels. In a report issued on January 14, Morgan Stanley also maintained a Hold rating on the stock with a $28.00 price target.
